MarketCap
Facebook
X
Telegram
Thermo Fisher Scientific Financial Ratios 2025-2006 | TMO
Brief overview of Thermo Fisher Scientific 's market valuation
Current figures are compared with the company's own five-year history for 2021–2025.
The latest available valuation ratios are P/E 29.26x (median 31.03x), EV/EBITDA 19.29x (median 22.42x), P/S 4.4x (median 4.81x). The multiple basket looks neutral against its history, differing from median levels by roughly -8.5%.
The 1/P/E calculation produces a 3.4% earnings yield. It does not capture future growth or capital structure.
End-period return metrics are ROE 12.6%, ROA 6.1%, ROCE 14.5%. Profitability remains positive and sufficient for normal operations without indicating exceptional efficiency.
PEG is 9.76x. Price is well ahead of embedded growth, making market expectations demanding.
The cash return period is stable at 63.9 days initially and 70 days at the end.
Overall assessment
Thermo Fisher Scientific 's market valuation is near its own historical norm, while quality ratios provide no extreme signal.
Annual Financial Ratios Thermo Fisher Scientific
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
P/E |
29.2 | 32.5 | 36.3 | 31.0 | 27.7 | 27.9 | 34.6 | 33.5 | 38.1 | 28.0 | 26.7 | 26.3 | 32.5 | 21.7 | 15.0 | 19.8 | 19.3 | 24.8 | 30.4 | - |
P/S |
4.4 | 4.8 | 5.0 | 4.8 | 5.5 | 5.5 | 5.0 | 4.0 | 4.1 | 3.1 | 3.1 | 3.0 | 3.2 | 2.0 | 1.7 | 2.0 | 1.7 | 2.4 | 2.3 | - |
EPS |
17.8 | 16.6 | 15.5 | 17.8 | 19.6 | 16.1 | 9.2 | 7.3 | 5.6 | 5.1 | 5.0 | 4.8 | 3.5 | 3.2 | 3.5 | 2.6 | 2.1 | 2.3 | 1.8 | - |
EV (Enterprise Value) |
186 B | 202 B | 208 B | 207 B | 210 B | 167 B | 154 B | 125 B | 115 B | 80.2 B | 71.7 B | 70.8 B | 50.6 B | 36.8 B | 30.8 B | 19.6 B | 14.9 B | 23 B | 22.1 B | -667 M |
EBITDA per Share |
23.3 | 22.2 | 20.5 | 23.9 | 27.6 | 21.3 | 14.7 | 13.9 | 11.8 | 10.2 | 9.45 | 8.13 | 6.8 | 6.35 | 5.24 | 4.78 | 4.21 | 4.69 | 4.11 | - |
EV/EBITDA |
21.2 | 23.8 | 26.3 | 22.1 | 19.3 | 23.0 | 24.3 | 20.7 | 22.4 | 18.0 | 17.2 | 19.5 | 18.8 | 13.8 | 13.0 | 10.2 | 8.6 | 11.7 | 12.8 | - |
PEG |
9.74 | 2.96 | 3.43 | 1.83 | 1.22 | 1.51 | 1.31 | 1.13 | 3.75 | 8.67 | 6.34 | 0.76 | 3.64 | -3.03 | 0.42 | - | - | - | - | - |
P/B |
1.8 | 2.1 | 2.2 | 2.2 | 2.3 | 2.6 | 4.3 | 3.6 | 3.3 | 2.6 | 2.5 | 2.4 | 2.5 | 1.7 | 1.3 | 1.0 | 0.8 | 1.2 | - | - |
P/CF |
25.1 | 23.7 | 25.7 | 23.6 | 23.0 | 21.4 | 31.6 | 26.0 | 24.2 | 20.9 | 22.0 | 22.7 | 24.0 | 14.9 | 14.0 | 13.7 | 9.9 | 17.1 | 15.4 | - |
ROE % |
12.58 | 12.78 | 12.74 | 15.83 | 18.92 | 18.47 | 12.45 | 10.65 | 8.76 | 9.39 | 9.25 | 9.22 | 7.55 | 7.62 | 8.84 | 6.74 | 5.51 | 6.57 | 5.17 | - |
ROA % |
6.09 | 6.51 | 6.03 | 7.16 | 8.12 | 9.24 | 6.33 | 5.22 | 3.93 | 4.40 | 4.83 | 4.42 | 4.00 | 4.29 | 4.96 | 4.85 | 3.93 | 4.65 | - | - |
ROCE % |
14.50 | 14.80 | 14.68 | 19.08 | 24.55 | 22.58 | 8.01 | 7.65 | 6.18 | 6.43 | 6.67 | 5.08 | 5.87 | 6.17 | 5.67 | 7.73 | 6.33 | 8.00 | 6.74 | - |
Current Ratio |
- | - | - | - | - | - | 1.9 | 1.7 | 1.3 | 1.4 | 1.4 | 1.2 | 3.2 | 2.3 | 1.5 | - | - | - | - | - |
DSO |
70.0 | 69.9 | 69.6 | 65.4 | 63.8 | 57.2 | 70.8 | 62.0 | 75.2 | 68.4 | 54.8 | 53.5 | 54.2 | 52.7 | 56.5 | 49.4 | 53.5 | 26.2 | - | - |
DIO |
- | - | - | - | - | - | 86.5 | 81.2 | 94.5 | 81.6 | 78.9 | 72.2 | 72.1 | 73.0 | 71.6 | - | - | - | - | - |
DPO |
- | - | - | - | - | - | 49.3 | 43.7 | 45.4 | 34.1 | 32.6 | 31.9 | 33.4 | 32.5 | 33.2 | - | - | - | - | - |
Operating Cycle |
70.0 | 69.8 | 69.6 | 65.4 | 63.9 | 57.2 | 157.3 | 143.2 | 169.7 | 150.0 | 133.7 | 125.7 | 126.3 | 125.7 | 128.0 | 49.4 | 53.5 | 26.2 | - | - |
Cash Conversion Cycle |
70.0 | 69.8 | 69.6 | 65.4 | 63.9 | 57.2 | 108.0 | 99.6 | 124.3 | 115.9 | 101.1 | 93.8 | 92.9 | 93.2 | 94.8 | 49.4 | 53.5 | 26.2 | - | - |
All numbers in USD currency
Quarterly Financial Ratios Thermo Fisher Scientific
| 2026-Q2 | 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | 2010-Q3 | 2010-Q2 | 2010-Q1 | 2009-Q3 | 2009-Q2 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
EPS |
4.68 | 4.44 | 4.28 | 4.28 | 3.99 | 4.26 | 4.05 | 3.47 | 4.44 | 3.53 | 3.34 | - | 3.82 | 4.25 | 5.66 | - | 4.83 | 4.65 | 5.93 | - | 4.88 | 2.92 | 1.99 | 2.51 | 1.89 | 2.8 | 2.04 | 2.23 | 1.76 | 1.87 | 1.44 | 1.32 | 1.35 | 1.57 | 1.41 | 1.6 | 1.2 | 1.31 | 1.02 | 1.51 | 1.19 | 1.28 | 0.97 | 1.5 | 1.18 | 0.7 | 1.38 | 0.95 | 0.88 | 0.77 | 0.94 | 1.05 | 0.8 | 0.64 | 0.76 | 0.77 | 0.7 | 1.37 | 0.65 | 0.67 | 0.58 | 0.57 | 540000 | 0.5 |
EBITDA per Share |
6.52 | 5.83 | 5.74 | 5.53 | 5.27 | 5.57 | 5.49 | 5.1 | - | - | 4.7 | - | 6.22 | 5.1 | 7.83 | - | 7.34 | 5.5 | 8.24 | - | 7.31 | 4.3 | 2.66 | - | 3.4 | 4.43 | 2.63 | - | 2.6 | 2.65 | 3.39 | - | 5.29 | 4.34 | 2.77 | - | 4.62 | 3.78 | 2.36 | - | 4.58 | 3.59 | 2.27 | - | 4.74 | 2.88 | 3.16 | - | 3.16 | 2.43 | 1.78 | - | 2.98 | 2.32 | 1.64 | - | 2.45 | 1.7 | 1.3 | 2.24 | 1.72 | 1.2 | 2.1 | 1.55 |
ROE % |
12.84 | 12.61 | 12.76 | 12.85 | 12.58 | 13.26 | 13.04 | 12.83 | 13.34 | 13.54 | 15.84 | 12.79 | 17.70 | 19.22 | 21.95 | 16.54 | 22.14 | 20.58 | 17.90 | 11.24 | 14.61 | 11.57 | 11.99 | 12.45 | 12.33 | 12.34 | 11.30 | 10.65 | 9.47 | 9.00 | 8.69 | 8.76 | 9.60 | 9.70 | 9.69 | 9.39 | 9.29 | 9.32 | 9.32 | 9.25 | 9.36 | 9.42 | 8.38 | 9.22 | 8.32 | 7.91 | 8.20 | 7.55 | 7.96 | 7.95 | 7.82 | 7.62 | 7.10 | 6.99 | 8.96 | 8.84 | 8.67 | 8.45 | 6.47 | 6.23 | 5.86 | 1.50 | 1.44 | 1.37 |
ROA % |
6.16 | 6.15 | 6.32 | 6.32 | 6.09 | 6.31 | 6.14 | 5.93 | 6.21 | 6.86 | 8.00 | 6.63 | 9.33 | 7.68 | 11.22 | 8.83 | 11.63 | 10.72 | 9.16 | 5.61 | 7.33 | 5.83 | 6.08 | 6.33 | 6.21 | 6.17 | 5.59 | 5.22 | 4.56 | 4.24 | 3.98 | 3.93 | 4.37 | 4.45 | 4.50 | 4.40 | 4.51 | 4.64 | 4.77 | 4.84 | 4.76 | 4.70 | 4.10 | 4.42 | 4.09 | 3.99 | 4.21 | 4.00 | 4.29 | 4.36 | 4.34 | 4.29 | 4.00 | 3.93 | 5.03 | 4.96 | 5.13 | 5.25 | 4.38 | 4.47 | 4.20 | 1.07 | 1.03 | 0.98 |
ROCE % |
14.98 | 14.50 | 14.66 | 14.70 | 14.72 | 15.36 | 15.21 | 15.06 | 15.33 | 15.94 | 19.22 | 15.52 | 21.40 | 23.35 | 27.32 | 20.44 | 27.47 | 25.63 | 22.38 | 13.69 | 16.87 | 14.89 | 13.95 | 11.33 | 14.64 | 14.84 | 12.65 | 9.55 | 12.05 | 11.69 | 10.73 | 7.88 | 10.39 | 10.86 | 10.32 | 7.88 | 10.51 | 10.79 | 10.11 | 7.71 | 10.83 | 9.88 | 11.35 | 9.07 | 11.40 | 10.51 | 11.11 | 6.85 | 9.13 | 9.18 | 9.29 | 6.99 | 9.09 | 8.58 | 8.34 | 6.00 | 8.07 | 8.00 | 8.13 | 7.78 | 7.43 | 1.89 | 1.79 | 1.72 |
DSO |
71.0 | 75.1 | 71.8 | 71.7 | 73.6 | 69.7 | 68.7 | 71.9 | 70.7 | 68.1 | 68.3 | - | 32.8 | 32.8 | 61.2 | - | 54.0 | 54.3 | 52.0 | - | 61.5 | 75.7 | 73.9 | 58.1 | 63.3 | 62.8 | 63.2 | 58.0 | 63.8 | 62.1 | 62.5 | 58.5 | 69.2 | 70.9 | 66.3 | 56.2 | 61.9 | 61.3 | 59.4 | 49.9 | 56.3 | 54.4 | 58.4 | 50.2 | 54.1 | 52.2 | 51.6 | 51.1 | 55.5 | 54.7 | 53.6 | 50.5 | 53.4 | 53.0 | 53.3 | 52.1 | 55.2 | 57.5 | 56.6 | 51.6 | 51.1 | 50.8 | 53.2 | - |
Operating Cycle |
- | - | 71.8 | 71.7 | 73.6 | 69.7 | 68.7 | 71.9 | 70.7 | 68.1 | 68.3 | - | 32.8 | 32.8 | 61.2 | - | 54.0 | 54.3 | 52.0 | - | 61.5 | 75.7 | 73.9 | 58.1 | 63.3 | 62.8 | 63.2 | 58.0 | 63.8 | 62.1 | 62.5 | 58.5 | 69.2 | 70.9 | 66.3 | 56.2 | 61.9 | 61.3 | 59.4 | 49.9 | 56.3 | 54.4 | 58.4 | 50.2 | 54.1 | 52.2 | 51.6 | 51.1 | 55.5 | 54.7 | 53.6 | 50.5 | 53.4 | 53.0 | 53.3 | 52.1 | 55.2 | 57.5 | - | - | - | - | - | - |
Cash Conversion Cycle |
- | - | 71.8 | 71.7 | 73.6 | 69.7 | 68.7 | 71.9 | 70.7 | 68.1 | 68.3 | - | 32.8 | 32.8 | 61.2 | - | 54.0 | 54.3 | 52.0 | - | 61.5 | 75.7 | 73.9 | 58.1 | 63.3 | 62.8 | 63.2 | 58.0 | 63.8 | 62.1 | 62.5 | 58.5 | 69.2 | 70.9 | 66.3 | 56.2 | 61.9 | 61.3 | 59.4 | 49.9 | 56.3 | 54.4 | 58.4 | 50.2 | 54.1 | 52.2 | 51.6 | 51.1 | 55.5 | 54.7 | 53.6 | 50.5 | 53.4 | 53.0 | 53.3 | 52.1 | 55.2 | 57.5 | - | - | - | - | - | - |
All numbers in USD currency
Multiples are an important financial analysis tool for the company Thermo Fisher Scientific , allowing investors and analysts to quickly assess the company’s value and investment attractiveness based on the ratio of market indicators to the company’s financial performance. Essentially, multiples express how the market values the company relative to its earnings, revenue, equity, or other key metrics.
Advantages of Using Financial Ratios- Simplified Data Analysis
Financial ratios transform large volumes of accounting data into compact and easily interpretable indicators, significantly simplifying the assessment of the company’s condition. - Comparability Between Companies
Multiples standardize financial metrics, enabling objective comparison of companies of different sizes, industries, and market capitalizations. - Identification of Trends and Issues
Regular analysis of ratios helps track the dynamics of financial health, identify strengths and weaknesses of the business, as well as potential risks. - Decision Support
Financial multiples serve as an important tool for investors, creditors, and company management in making investment, credit, and managerial decisions. - Accelerated Assessment of Investment Attractiveness
Ratios allow quick determination of key performance, liquidity, and financial stability indicators, facilitating prompt evaluation of companies’ attractiveness for investments.
Using multiples enables comparison between companies, even if they differ in size or industry, as they standardize financial data into ratios convenient for analysis. This is especially useful for evaluating companies where direct analysis of financial statements may be complex or require in-depth knowledge.
Britain
USA
Germany
China
Australia
Israel
Niderland
Canada
Irlanda
